Kronos Bio

Kronos Bio

Kronos Bio is a Cambridge, Massachusetts-based therapeutics company working on research and development of therapies that modulate historically recalcitrant cancer targets.

No article has been written about this topic yet.
Paste a URL about this topic to auto-extract knowledge.
Visit our Writing Guide for help on how to write about a topic,
and check out an example of a well filled out topic page.

No article has been written about this topic yet.
Be the first one to add some text.

Loading AI-assisted edit mode...

Timeline

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
Kronos Bio, Inc. funding round, July 2019
105,000,000
July 2019
4 Results
Page 1 of 1
Results per page:
Powered by Golden Research Engine

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Nick Paul
July 16, 2020
FierceBiotech
Ex-Gilead CSO Norbert Bischofberger has struck a deal with his former employer. The agreement will see Bischofberger's Kronos Bio buy Gilead's portfolio of spleen tyrosine kinase inhibitors and vault into clinical development.
BioSpace
May 19, 2020
BioSpace
Kronos Bio, Inc., dedicated to drugging transcriptional regulatory networks in cancer, announced expansion to its clinical development team with the appointment of Zung To as Vice President, Clinical Operations. In this new position, Mr. To will assist in defining developmental strategy, guiding clinical protocol design and study conduct. He will report to Jorge DiMartino M.D., Ph.D., the company'
Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.